Xcout IntelBenitec Biopharma Inc.
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. Its Silence and Replace, a DNA-directedRNA interference platform combines RNA interference with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The company is developing BB-301, an AAV-based gene therapy designed to silence the expression of the disease-causing gene for the treatment of oculopharyngeal muscular dystrophy related dysphagia. Benitec Biopharma Inc. is headquartered in Hayward, California.
Subscribe to see Benitec Biopharma Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Benitec Biopharma Inc. at a glance
Benitec Biopharma Inc. is a biotechnology company headquartered in Hayward, United States. It is publicly listed (BNTC) with a market capitalisation of $304.7M. Xcout tracks 18 named people at Benitec Biopharma Inc., including Jerel A. Banks (Executive Chairman & Chief Executive Officer).
Benitec Biopharma Inc. leadership
- Jerel A. BanksExecutive Chairman & Chief Executive Officer
- Jerel Banks, M.D., Ph.D.Chief Executive Officer & Chairman of the Board
- Sophie MukadamChief Operating Officer
- Megan Joan BostonCFO & Secretary
- Claudia KlothSenior Vice President of Manufacturing
- Michael GrahamHead of Discovery & Founding Scientist
12 more named people on record for Benitec Biopharma Inc., with roles, board committees and tenure — see the full roster →
Benitec Biopharma Inc. competitors
A few of Benitec Biopharma Inc.'s closest competitors — see the full list of competitors and alternatives →
Dyne Therapeutics, Inc. is a U.S.-based biotechnology firm focused on developing advanced treatments for genetically driven muscle disorders. Utilizing its proprietary FORCE platform, which is engineered to deliver disease-modifying therapeutics, the company is actively engaged in various programs. These initiatives target conditions such as myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral dystrophy, in addition to other rare skeletal, cardiac, and metabolic muscle diseases. The company was founded in 2017 and maintains its corporate headquarters in Waltham, Massachusetts.
Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial. The company develops its products through gene addition, gene editing, gene silencing, and cellular regeneration. It has a research collaboration agreement with Alnylam Pharmaceuticals, Inc. to identify and validate novel gene targets for the potential treatment of cardiovascular disease. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
BreezeBio is a biotechnology company headquartered in the South San Francisco area of California that develops precision genetic medicines.
Solid Biosciences Inc. is an American biotechnology firm dedicated to creating therapeutic solutions for Duchenne Muscular Dystrophy (DMD). Its most advanced experimental drug, SGT-001, is a gene transfer treatment currently in Phase I/II clinical trials, designed to encourage the production of functional dystrophin protein in patients' muscles. The company is also progressing with SGT-003, which represents a next-generation gene transfer therapy intended for DMD. Beyond specific drug candidates, Solid Biosciences is actively developing innovative platform technologies, such as "dual gene expression," a technique that allows for multiple therapeutic genes to be bundled into a single viral vector, and researching new capsid designs. The company maintains a strategic alliance through a collaboration and license agreement with Ultragenyx Pharmaceutical Inc., focusing on the joint development and market introduction of novel gene therapies for Duchenne Muscular Dystrophy. Founded in 2013, Solid Biosciences Inc. conducts its operations from its headquarters in Cambridge, Massachusetts.
ReCode Therapeutics is a clinical-stage genetic medicines company headquartered in Menlo Park, California, and Durham, North Carolina. The company leverages proprietary delivery systems to power a new class of disease-modifying genetic therapies.
Skylark Bio is a biotechnology company developing precision-targeted, locally delivered gene therapies to treat genetic hearing loss and other single-gene disorders. The company's platform aims to restore natural biological processes and hearing function, addressing conditions that affect children and individuals with genetic communication impairments.
Get Benitec Biopharma Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Benitec Biopharma Inc. in Xcout Intel
- 18 named people with titles, LinkedIn and board committees
- The full competitor set, tracking, exports and API access